45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
16,244
Insurances with rates
27
CPT / HCPCS codes
0
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J022500000 | Vutrisiran 25mg/0.5ml Syringe | $363,381 | $345,212 | — | — | 3 |
| J022500000 | Vutrisiran 25mg/0.5ml Syringe | $363,381 | $345,212 | — | — | 17 |
| J022500000 | Vutrisiran 25mg/0.5ml Syringe | $363,381 | $345,212 | — | — | 14 |
| J182300000 | Inebilizumab-cdon 100mg/10ml | $142,335 | $135,219 | — | — | 3 |
| J182300000 | Inebilizumab-cdon 100mg/10ml | $142,335 | $135,219 | — | — | 17 |
| J182300000 | Inebilizumab-cdon 100mg/10ml | $142,335 | $135,219 | — | — | 14 |
| J235100000 | Ocrelizumab Hyal-ocsq 920mg Vl | $125,689 | $119,404 | — | — | 3 |
| J235100000 | Ocrelizumab Hyal-ocsq 920mg Vl | $125,689 | $119,404 | — | — | 17 |
| J235100000 | Ocrelizumab Hyal-ocsq 920mg Vl | $125,689 | $119,404 | — | — | 14 |
| J934700000 | Tremelimumab-ACTL 300mg/15ml | $123,538 | $117,361 | — | — | 3 |
| J934700000 | Tremelimumab-ACTL 300mg/15ml | $123,538 | $117,361 | — | — | 17 |
| J934700000 | Tremelimumab-ACTL 300mg/15ml | $123,538 | $117,361 | — | — | 14 |
| J922800000 | Ipilimumab 200mg Vial | $94,117 | $89,412 | — | — | 3 |
| J922800000 | Ipilimumab 200mg Vial | $94,117 | $89,412 | — | — | 17 |
| J922800000 | Ipilimumab 200mg Vial | $94,117 | $89,412 | — | — | 14 |
| J717000002 | Emicizumab-kxwh 300mg/2mL Vial | $92,028 | $87,426 | — | — | 3 |
| J717000002 | Emicizumab-kxwh 300mg/2mL Vial | $92,028 | $87,426 | — | — | 17 |
| J717000002 | Emicizumab-kxwh 300mg/2mL Vial | $92,028 | $87,426 | — | — | 14 |
| J935900000 | Loncastuximab-Lpyl 10mg Vial | $71,549 | $67,972 | — | — | 3 |
| J935900000 | Loncastuximab-Lpyl 10mg Vial | $71,549 | $67,972 | — | — | 17 |
| J935900000 | Loncastuximab-Lpyl 10mg Vial | $71,549 | $67,972 | — | — | 14 |
| J130300000 | Ravulizumab-CWVZ 1100mg vial | $71,492 | $67,918 | — | — | 3 |
| J130300000 | Ravulizumab-CWVZ 1100mg vial | $71,492 | $67,918 | — | — | 17 |
| J130300000 | Ravulizumab-CWVZ 1100mg vial | $71,492 | $67,918 | — | — | 14 |
| J927400000 | Tebentafusp-TEBN 100mcg/0.5ml | $63,907 | $60,712 | — | — | 3 |
| J927400000 | Tebentafusp-TEBN 100mcg/0.5ml | $63,907 | $60,712 | — | — | 17 |
| J927400000 | Tebentafusp-TEBN 100mcg/0.5ml | $63,907 | $60,712 | — | — | 14 |
| J250700000 | Pegloticase 8Mg Vial | $62,181 | $59,072 | — | — | 3 |
| J250700000 | Pegloticase 8Mg Vial | $62,181 | $59,072 | — | — | 17 |
| J250700000 | Pegloticase 8Mg Vial | $62,181 | $59,072 | — | — | 14 |
| J933300000 | Rozanolixizumab-noli 840mg/6ml | $56,650 | $53,818 | — | — | 3 |
| J933300000 | Rozanolixizumab-noli 840mg/6ml | $56,650 | $53,818 | — | — | 17 |
| J933300000 | Rozanolixizumab-noli 840mg/6ml | $56,650 | $53,818 | — | — | 14 |
| J235000000 | Ocrelizumab 300mg Vial | $51,851 | $49,259 | — | — | 3 |
| J235000000 | Ocrelizumab 300mg Vial | $51,851 | $49,259 | — | — | 17 |
| J235000000 | Ocrelizumab 300mg Vial | $51,851 | $49,259 | — | — | 14 |
| J717000001 | Emicizumab-kxwh 150mg/mL Vial | $46,014 | $43,713 | — | — | 3 |
| J717000001 | Emicizumab-kxwh 150mg/mL Vial | $46,014 | $43,713 | — | — | 17 |
| J717000001 | Emicizumab-kxwh 150mg/mL Vial | $46,014 | $43,713 | — | — | 14 |
| J902600000 | Tarlatamab-DLLE 10mg/4.2ml Vl | $45,670 | $43,386 | — | — | 3 |
| J902600000 | Tarlatamab-DLLE 10mg/4.2ml Vl | $45,670 | $43,386 | — | — | 17 |
| J930900001 | Polatuzumab Vedotin 140mg | $45,670 | $43,386 | — | — | 3 |
| J930900001 | Polatuzumab Vedotin 140mg | $45,670 | $43,386 | — | — | 17 |
| J902600000 | Tarlatamab-DLLE 10mg/4.2ml Vl | $45,670 | $43,386 | — | — | 14 |
| J930900001 | Polatuzumab Vedotin 140mg | $45,670 | $43,386 | — | — | 14 |
| J324100000 | Teprotumumab-TRBW 500mg | $45,365 | $43,097 | — | — | 3 |
| J324100000 | Teprotumumab-TRBW 500mg | $45,365 | $43,097 | — | — | 17 |
| J324100000 | Teprotumumab-TRBW 500mg | $45,365 | $43,097 | — | — | 14 |
| J162800001 | Guselkumab 200mg/20ml Vial | $44,327 | $42,111 | — | — | 3 |
| J162800001 | Guselkumab 200mg/20ml Vial | $44,327 | $42,111 | — | — | 17 |
Showing top 50 of 16,244 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.